The data strengthens EXPAREL's value proposition to payers and providers, potentially driving formulary adoption and reimbursement in outpatient orthopedic settings. Traders should monitor for increased commercial traction and potential pull-through in ZILRETTA and iovera° given shared commercial infrastructure.
PCRX drugs
PCRX drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 13 $24.06entry
- T+1 · 7mo ago −1.29%α −2.50% · $23.75
- T+5 · 7mo ago +3.49%α +0.20% · $24.90
- T+20 · 6mo ago −5.49%α −13.21% · $22.74
- T+60 · 4mo ago +6.07%α −2.85% · $25.52
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Pacira BioSciences presented real-world data at AMCP 2026 showing EXPAREL® use in outpatient joint replacement surgeries is associated with lower total healthcare costs and reduced opioid utilization, particularly in patients with low back pain and in teaching hospitals. The findings reinforce EXPAREL's economic value and non-opioid pain management benefits.
Key Facts
- EXPAREL use in THA was associated with lower total healthcare costs at 3 months ($7,332 vs $8,153) and 6 months ($13,022 vs $15,081) compared to non-LB.
- In patients with low back pain, EXPAREL showed significantly lower costs at 6 months ($13,614 vs $18,652) and reduced opioid use by 51 MMEs at 6 months.
- In TKA at teaching hospitals, EXPAREL was linked to statistically significant cost savings at surgical visit, 7 days, and 30 days post-op.
- A 3-year budget model projected $117,868 in cumulative cost savings per 1 million members with EXPAREL vs ropivacaine.
Financial Impact
Projected cumulative cost savings of $117,868 per 1 million members over 3 years; per-member-per-month savings of $0.003
Risk Factors
- Real-world studies show association, not causation, and may not translate into increased prescribing.
- Forward-looking statements are subject to risks including regulatory, commercial execution, and clinical trial uncertainties.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3272431 |
Track record
29 reports on PCRX
5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +42.26% at T+60 after the Aug 6, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Bearish 6/10 Entry $36.46 Now $36.48 −0.05% settles Dec 14
- Nov 12, 20264d ago SC TO-T/A Mixed 7/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
- Nov 12, 20264d ago SC 14D-9/A Neutral 3/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $36.43 Now $36.48 +0.14% settles Dec 7
- Nov 3, 202613d ago SC 14D-9/A Neutral 3/10 Entry $36.40 Now $36.48 +0.22% settles Dec 3
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 30, 202617d ago SC 14D-9 Bullish 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 30, 202617d ago SC TO-T Mixed 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 13, 20264w ago SC 13D/A Bearish 7/10 Entry $36.40 to $36.46 Now $36.48 −0.22% ▼ −0.16% −1.44% vs SPY
- Oct 8, 20265w ago SC TO-C Bullish 7/10 Entry $36.31 to $36.43 Now $36.48 +0.47% ▲ +0.33% +5.89% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers